Early-stage triple-negative breast cancer patients with high immune cell levels have lower recurrence risks and better survival rates, even without chemotherapy.
A multicenter international study published in JAMA suggests that early-stage triple-negative breast cancer (TNBC) patients with high levels of immune cells in their tumors have lower recurrence risks and better survival rates, even without chemotherapy. TNBC, which does not respond to estrogen receptor or HER2 protein drugs, is more common in younger people and those of African American, Hispanic, and Indian descent. Immune cells, or tumor-infiltrating lymphocytes (TILs), are naturally existing immune system cells that move from the bloodstream into tumors.
April 02, 2024
5 Articles